semaglutide trevogrumab and garetosmab Factbox-Fat, not muscle: Drugmakers in race for next weight-loss breakthrough Emerging pharmacotherapies for obesity: A

Place of insulin in type 2 diabetes Insulin is a useful and effective glucose-lowering agent (Fig

People with eating disorders are turning to Ozempic People with eating disorders are more likely to be on GLP-1 drugs, such as Ozempic or Wegovy, according to new research

Month 6 and beyond: Weight loss may continue at a slower pace through month 12 and even beyond

With rapid weight loss, losing weight faster than the skin can shrink is common

Unfortunately, the current trend is completely the opposite, with a steady increase in overweight and obesity affecting the youngest, putting them at very high risk of developing a veritable epidemic of cardiometabolic diseases in a few years (see our article on this subject)